DiaMedica Therapeutics Inc. (DMAC)

Market Cap	306.60M +85.4%
Revenue (ttm)	n/a
Net Income	-35.10M
EPS	-0.71
Shares Out	53.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,314
Open	5.60
Previous Close	5.72
Day's Range	5.50 - 5.72
52-Week Range	3.48 - 10.42
Beta	0.99
Analysts	Strong Buy
Price Target	15.50 (+172.41%)
Earnings Date	May 6, 2026

About DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: DMAC
• Website: https://www.diamedica.com

Analyst Summary

According to 5 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 172.41% from the latest price.

Price Target

$15.5

(172.41% upside)

Analyst Consensus: Strong Buy